Anti-RSV [RSHZ19 (Felvizumab)]

Absolute Antibody

Anti-RSV [RSHZ19 (Felvizumab)]

7

This antibody is specific for the an epitope located between amino acids 417-432 of conserved fusion (F) protein of RSV.

Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

Functional Assay, ELISA

functional; ELISA

Research Use Only

Monoclonal

RSHZ19 (Felvizumab)

Human

IgG1

This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Virus

RSV

This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.

-20°C,2°C to 8°C

12352203